Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia

Charalambos Xanthopoulos, Effie Kostareli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Downloads (Pure)


Purpose of Review
The development and progression of chronic lymphocytic leukemia (CLL), a highly heterogenous B cell malignancy, are influenced by both genetic and environmental factors. Environmental factors, including pharmacological interventions, can affect the epigenetic landscape of CLL and thereby determine the CLL phenotype, clonal evolution, and clinical outcome. In this review, we critically present the latest advances in the field of CLL epigenomics/epigenetics in order to provide a systematic overview of to-date achievements and highlight the potential of epigenomics approaches in light of novel treatment therapies.

Recent Findings
Recent technological advances have enabled broad and precise mapping of the CLL epigenome. The identification of CLL-specific DNA methylation patterns has allowed for accurate CLL subtype definition, a better understanding of clonal origin and evolution, and the discovery of reliable biomarkers. More recently, studies have started to unravel the prognostic, predictive, and therapeutic potential of mapping chromatin dynamics and histone modifications in CLL. Finally, analysis of non-coding RNA expression has indicated their contribution to disease pathogenesis and helped to define prognostic subsets in CLL.

Overall, the potential of CLL epigenomics for predicting treatment response and resistance is mounting, especially with the advent of novel targeted CLL therapies.
Original languageEnglish
Pages (from-to)214–226
JournalCurrent Genetic Medicine Reports
Early online date27 Nov 2019
Publication statusPublished - Dec 2019


Dive into the research topics of 'Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia'. Together they form a unique fingerprint.

Cite this